切换至 "中华医学电子期刊资源库"

中华神经创伤外科电子杂志 ›› 2020, Vol. 06 ›› Issue (05) : 270 -274. doi: 10.3877/cma.j.issn.2095-9141.2020.05.004

所属专题: 文献

临床研究

长期口服抗血小板药物合并急性硬膜下血肿的临床分析
张永明1,(), 赵鹏程2, 武孝刚3, 黄振山3, 许少年3, 马涛3   
  1. 1. 230041 合肥,安徽省第二人民医院神经外科
    2. 230031 合肥,安徽医科大学解放军临床学院
    3. 230031 合肥,解放军联勤保障部队第九〇一医院神经外科
  • 收稿日期:2020-06-05 出版日期:2020-10-15
  • 通信作者: 张永明
  • 基金资助:
    安徽省重点研究与开发项目(201904a07020108)

Clinical analysis of traumatic subdural hematoma with long-term oral antiplatelet drugs

Yongming Zhang1,(), Pengcheng Zhao2, Xiaogang Wu3, Zhenshan Huang3, Shaonian Xu3, Tao Ma3   

  1. 1. Department of Neurosurgery, Anhui No.2 Provincial People’s Hospital, Hefei 230041, China
    2. PLA Clinical College, Anhui Medical University, Hefei 230031, China
    3. Department of Neurosurgery, The 901st Hospital of the Joint Logistics Support Force of PLA, Hefei 230031, China
  • Received:2020-06-05 Published:2020-10-15
  • Corresponding author: Yongming Zhang
  • About author:
    Corresponding author: Zhang Yongming, Email:
引用本文:

张永明, 赵鹏程, 武孝刚, 黄振山, 许少年, 马涛. 长期口服抗血小板药物合并急性硬膜下血肿的临床分析[J/OL]. 中华神经创伤外科电子杂志, 2020, 06(05): 270-274.

Yongming Zhang, Pengcheng Zhao, Xiaogang Wu, Zhenshan Huang, Shaonian Xu, Tao Ma. Clinical analysis of traumatic subdural hematoma with long-term oral antiplatelet drugs[J/OL]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2020, 06(05): 270-274.

目的

分析长期口服抗血小板药物合并急性硬膜下血肿(ASDH)患者的临床治疗策略及疗效。

方法

回顾性分析解放军联勤保障部队第九〇一医院神经外科自2018年1月至12月手术治疗的ASDH患者67例。口服抗血小板药物者32例,其中服用阿司匹林者(单抗组)20例,服用阿司匹林+氯吡格雷药物者(双抗组)12例,未服用抗血小板药物者(对照组)35例。对比分析3组患者术前凝血指标、术中失血量、术后硬膜外引流量、再出血及二次手术率等指标,所有患者随访6个月以上,对比分析3组患者的GOS评分和改良Rankin量表(mRs)评分。

结果

与对照组相比,单抗组与双抗组的出血时间、双抗组的部分凝血活酶时间显著延长,且术中出血量及术后硬膜外引流量均显著增多,差异均有统计学意义(P<0.05)。单抗组3例(15.00%)、双抗组4例(33.33%)及对照组1例(2.86%)术后发生再出血行二次手术。随访6个月以上,单抗组与双抗组的GOS评分及mRs评分较低,恢复良好率较对照组显著降低(P<0.05)。

结论

长期口服抗血小板药物药物可加重ASDH的病情,术中止血困难、出血多,术后再出血率高,降低了远期神经功能恢复。

Objective

To investigate the treatment strategies and effect of acute subdural hematoma (ASDH) with long-term oral antiplatelet drugs.

Methods

Sixty seven patients with ASDH underwent surgical treatment from January 2018 to December 2018 in Neurosurgery Department of The 901st Hospital of the Joint Logistics Support Force of PLA. Thirty two patients were treated with oral antiplatelet drugs, including 20 patients taking aspirin (aspirin-single group), 12 patients taking aspirin+clopidogrel (double antibody group), and 35 patients did not take antiplatelet drugs (control group). The preoperative coagulation indexes, intraoperative blood loss, postoperative epidural drainage flow, further hemorrhage and secondary surgery rate of 3 groups were compared and analyzed. All patients were followed up for more than 6 months, the GOS score and modified Rankin scale (mRs) score of 3 groups were compared and analyzed.

Results

Compared with control group, the bleeding time, activated partial thromboplastin time were significantly prolonged, and the intraoperative blood loss and postoperative epidural drainage flow were significantly increased in spirin-single group and double antibody group (P<0.05). Three cases (15.00%) in spirin-single group, 4 cases (33.33%) in double antibody group and 1 case (2.86%) in control group had been undergone secondary surgery dued to rehemorrhage after the first operation. After 6 months of follow-up, good recovery rate measured by GOS scores and mRs score in spirin-single group and double antibody group were significantly decreased than the control group (P<0.05).

Conclusion

Long-term oral antiplatelet drugs can aggravate the condition of ASDH, such as more bleeding and not easy to stop bleeding intraoperative, high rehemorrhage rate after operative, and hinder the neural functional recovery long-time outcome.

表1 3组患者的一般资料比较(±s
表2 3组患者的围手术期凝血指标比较(±s
表3 3组患者术中、术后并发症发生率比较
表4 3组患者术后6个月预后结果比较
图1 抗血小板合并急性硬膜下血肿患者急诊手术及二次出血术前术后CT图
[1]
Zazulia A. Antiplatelet and anticoagulant therapy after intracerebral hemorrhage[J]. Neurol Clin, 2015, 33(2): 329-345.
[2]
颜小荣,康德智.脑挫裂伤后脑内血肿进展性扩大的危险因素[J].中华神经创伤外科电子杂志, 2017, 3(1): 51-53.
[3]
江基尧.中国颅脑创伤诊治的未来[J].中华神经创伤外科电子杂志, 2019, 5(5): 257-259.
[4]
Greuter L, Ullmann M, Mariani L, et al. Effect of preoperative antiplatelet or anticoagulation therapy on hemorrhagic complications in patients with traumatic brain injury undergoing craniotomy or craniectomy[J]. Neurosurg Focus, 2019, 47(5): E3.
[5]
Schaefer PW, Huisman TA, Sorensen AG, et al. Diffusion-weighted MR imaging in closed head injury: high correlation with initial glasgow coma scale score and score on modified Rankin scale at discharge[J]. Radiology, 2004, 233(1): 58-66.
[6]
Sprügel MI, Kuramatsu JB, Gerner ST, et al. Antiplatelet therapy in primary spontaneous and oral anticoagulation-associated intracerebral hemorrhage[J]. Stroke, 2018, 49(11): 2621-2629.
[7]
罗国君,牛富生,张磊,等.系统评价抗血小板药物的使用对脑内微出血的影响[J].神经损伤与功能重建, 2017, 12(5): 392-395.
[8]
孙青,刘永春,张东平,等.抗凝、抗血小板药物相关性脑出血28例临床分析[J].江苏医药, 2019, 45(9): 909-912.
[9]
Kunio NR, Differding JA, Watson KM, et al. Thrombelastography-identified coagulopathy is associated with increased morbidity and mortality after traumatic brain injury[J]. Am J Surg, 2012, 203(5): 584-588.
[10]
Gozal YM, Carroll CP, Krueger BM, et al. Point-of-care testing in the acute management of traumatic brain injury: identifying the coagulopathic patient[J]. Surg Neurol Int, 2017, 8: 48.
[11]
Prinz V, Finger T, Bayerl S, et al. High prevalence of pharmacologically induced platelet dysfunction in the acute setting of brain injury[J]. Acta Neurochir (Wien), 2016, 158(1): 117-123.
[12]
Camps-Renom P, Alejaldre-Monforte A, Delgado-Mederos R, et al. Does prior antiplatelet therapy influence hematoma volume and hematoma growth following intracerebral hemorrhage? Results from a prospective study and a meta-analysis[J]. Eur J Neurol, 2017, 24(2): 302-308.
[13]
Briggs A, Gates JD, Kaufman RM, et al. Platelet dysfunction and platelet transfusion in traumatic brain injury[J]. J Surg Res, 2015, 193(2): 802-806.
[14]
Signorelli SS, Platania I, Tomasello SD, et al. Insights from experiences on antiplatelet drugs in stroke prevention: a review[J]. Int J Environ Res Public Health, 2020, 17(16): 5840.
[15]
Bouget J, Balusson F, Viglino D, et al. Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice: a prospective cohort study[J]. PLoS One, 2020, 15(8): e0237022.
[1] 王守森, 傅世龙, 鲜亮, 林珑. 深入理解控制性减压技术对创伤性颅脑损伤术中脑膨出的预防机制与效果[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 257-262.
[2] 吴东阳, 林向丹, 石佐林, 赵玉龙, 王振, 文安国, 纪鑫, 李俊之, 赵明光. NF-L、NLRP3、S100B 蛋白在颅脑损伤严重程度及预后评估中的应用价值[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 279-285.
[3] 罗磊, 熊建平, 郑宏伟, 王嗣嵩, 柴祥, 吴青, 潘海鹏. 静脉留置针穿刺引流治疗颅骨修补术后硬膜外积液一例报道[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 315-317.
[4] 从长春, 王春琳, 武孝刚, 王金标, 章福彬, 孙磊, 王李. 重型颅脑损伤患者呼吸机相关性肺炎的危险因素及病原学分析[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(03): 151-157.
[5] 毛进鹏, 陶治鹤, 刘琦, 王勇, 周明安, 陈劲松, 田少斌. 保守治疗大量创伤性硬膜外血肿的体会(附10例报告)[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(03): 164-168.
[6] 辛强, 朱文豪, 何川, 李文臣, 陈勃, 王海峰. 神经胶质细胞来源的外泌体miRNAs对创伤性颅脑损伤后神经炎症的影响[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(03): 169-173.
[7] 鹿海龙, 朱玉辐, 贺雪凤, 蔡廷江, 王栋, 朱圣玲, 张恩刚, 王策. 创伤性颅脑损伤二次手术的危险因素分析及预警模型构建[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(02): 97-101.
[8] 刘彪, 巍山, 关永胜. 基于Rotterdam CT评分及凝血功能指标的创伤性颅脑损伤预后预测模型的构建与验证[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(01): 22-27.
[9] 罗丹, 柏宋磊, 易峰. HMGB1-TLR2/TLR4/RAGE通路与颅脑损伤并发认知功能障碍病情变化的关系研究[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(01): 28-34.
[10] 袁宝玉, 管义祥, 王东流, 陆正. 不同时机颅骨修补术治疗颅脑外伤的临床疗效[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(01): 35-41.
[11] 李鑫, 刘炳辉, 程名, 王凡, 刘玉明, 周绍明. 基于Rotterdam CT评分评估的颅脑损伤术中控制性减压的临床应用价值[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(01): 16-21.
[12] 吕伟豪, 费晓炜, 武秀权, 何鑫, 郇宇, 吴霜, 豆雅楠, 费舟, 胡世颉. 重型颅脑损伤合并应激性高血糖患者血糖水平与预后的关系[J/OL]. 中华神经创伤外科电子杂志, 2023, 09(06): 338-342.
[13] 胡志恒, 任洪波, 宋志远, 张运刚, 韩晓正. 血清sTIM-3及其配体Gal-9、CEACAM-1与创伤性颅脑损伤患者脑损伤程度及预后的关系[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(04): 201-207.
[14] 黄锦, 温静, 李佳霖, 韩丹, 刘翠华, 杨殿辉, 张洋洋. 双联抗血小板药物对溃疡性结肠炎患者的影响及处理策略[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(03): 195-199.
[15] 李建, 张立, 高嵘, 倪海波, 宋照明, 陈周青, 王中. 创伤性脑血管损伤的识别和治疗[J/OL]. 中华脑血管病杂志(电子版), 2023, 17(06): 596-603.
阅读次数
全文


摘要